Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
BACKGROUND: Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics. However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed. METHODOLOGY/PRINCIPAL FINDINGS: Here, we propose a novel HDAC inhibitor, N-Hydroxy-4-(4-phenyl...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3261198?pdf=render |
| _version_ | 1818154360339693568 |
|---|---|
| author | Jiunn-Min Shieh Tzu-Tang Wei Yen-An Tang Sin-Ming Huang Wei-Ling Wen Mei-Yu Chen Hung-Chi Cheng Santosh B Salunke Ching-Shih Chen Pinpin Lin Chien-Tien Chen Yi-Ching Wang |
| author_facet | Jiunn-Min Shieh Tzu-Tang Wei Yen-An Tang Sin-Ming Huang Wei-Ling Wen Mei-Yu Chen Hung-Chi Cheng Santosh B Salunke Ching-Shih Chen Pinpin Lin Chien-Tien Chen Yi-Ching Wang |
| author_sort | Jiunn-Min Shieh |
| collection | DOAJ |
| description | BACKGROUND: Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics. However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed. METHODOLOGY/PRINCIPAL FINDINGS: Here, we propose a novel HDAC inhibitor, N-Hydroxy-4-(4-phenylbutyryl-amino) benzamide (HTPB), as a potential chemotherapeutic drug for solid tumors. The HDAC inhibition of HTPB was confirmed using HDAC activity assay. The antiproliferative and anti-migratory mechanisms of HTPB were investigated by cell proliferation, flow cytometry, DNA ladder, caspase activity, Rho activity, F-actin polymerization, and gelatin-zymography for matrix metalloproteinases (MMPs). Mice with tumor xenograft and experimental metastasis model were used to evaluate effects on tumor growth and metastasis. Our results indicated that HTPB was a pan-HDAC inhibitor in suppressing cell viability specifically of lung cancer cells but not of the normal lung cells. Upon HTPB treatment, cell cycle arrest was induced and subsequently led to mitochondria-mediated apoptosis. HTPB disrupted F-actin dynamics via downregulating RhoA activity. Moreover, HTPB inhibited activity of MMP2 and MMP9, reduced integrin-β1/focal adhesion complex formation and decreased pericellular poly-fibronectin assemblies. Finally, intraperitoneal injection or oral administration of HTPB efficiently inhibited A549 xenograft tumor growth in vivo without side effects. HTPB delayed lung metastasis of 4T1 mouse breast cancer cells. Acetylation of histone and non-histone proteins, induction of apoptotic-related proteins and de-phosphorylation of focal adhesion kinase were confirmed in treated mice. CONCLUSIONS/SIGNIFICANCE: These results suggested that intrinsic apoptotic pathway may involve in anti-tumor growth effects of HTPB in lung cancer cells. HTPB significantly suppresses tumor metastasis partly through inhibition of integrin-β1/FAK/MMP/RhoA/F-actin pathways. We have provided convincing preclinical evidence that HTPB is a potent HDAC targeted inhibitor and is thus a promising candidate for lung cancer chemotherapy. |
| first_indexed | 2024-12-11T14:25:16Z |
| format | Article |
| id | doaj.art-a025c5ef0e7d4542a2a37989be608fb4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T14:25:16Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a025c5ef0e7d4542a2a37989be608fb42022-12-22T01:02:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0171e3024010.1371/journal.pone.0030240Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.Jiunn-Min ShiehTzu-Tang WeiYen-An TangSin-Ming HuangWei-Ling WenMei-Yu ChenHung-Chi ChengSantosh B SalunkeChing-Shih ChenPinpin LinChien-Tien ChenYi-Ching WangBACKGROUND: Compound targeting histone deacetylase (HDAC) represents a new era in molecular cancer therapeutics. However, effective HDAC inhibitors for the treatment of solid tumors remain to be developed. METHODOLOGY/PRINCIPAL FINDINGS: Here, we propose a novel HDAC inhibitor, N-Hydroxy-4-(4-phenylbutyryl-amino) benzamide (HTPB), as a potential chemotherapeutic drug for solid tumors. The HDAC inhibition of HTPB was confirmed using HDAC activity assay. The antiproliferative and anti-migratory mechanisms of HTPB were investigated by cell proliferation, flow cytometry, DNA ladder, caspase activity, Rho activity, F-actin polymerization, and gelatin-zymography for matrix metalloproteinases (MMPs). Mice with tumor xenograft and experimental metastasis model were used to evaluate effects on tumor growth and metastasis. Our results indicated that HTPB was a pan-HDAC inhibitor in suppressing cell viability specifically of lung cancer cells but not of the normal lung cells. Upon HTPB treatment, cell cycle arrest was induced and subsequently led to mitochondria-mediated apoptosis. HTPB disrupted F-actin dynamics via downregulating RhoA activity. Moreover, HTPB inhibited activity of MMP2 and MMP9, reduced integrin-β1/focal adhesion complex formation and decreased pericellular poly-fibronectin assemblies. Finally, intraperitoneal injection or oral administration of HTPB efficiently inhibited A549 xenograft tumor growth in vivo without side effects. HTPB delayed lung metastasis of 4T1 mouse breast cancer cells. Acetylation of histone and non-histone proteins, induction of apoptotic-related proteins and de-phosphorylation of focal adhesion kinase were confirmed in treated mice. CONCLUSIONS/SIGNIFICANCE: These results suggested that intrinsic apoptotic pathway may involve in anti-tumor growth effects of HTPB in lung cancer cells. HTPB significantly suppresses tumor metastasis partly through inhibition of integrin-β1/FAK/MMP/RhoA/F-actin pathways. We have provided convincing preclinical evidence that HTPB is a potent HDAC targeted inhibitor and is thus a promising candidate for lung cancer chemotherapy.http://europepmc.org/articles/PMC3261198?pdf=render |
| spellingShingle | Jiunn-Min Shieh Tzu-Tang Wei Yen-An Tang Sin-Ming Huang Wei-Ling Wen Mei-Yu Chen Hung-Chi Cheng Santosh B Salunke Ching-Shih Chen Pinpin Lin Chien-Tien Chen Yi-Ching Wang Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. PLoS ONE |
| title | Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. |
| title_full | Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. |
| title_fullStr | Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. |
| title_full_unstemmed | Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. |
| title_short | Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. |
| title_sort | mitochondrial apoptosis and fak signaling disruption by a novel histone deacetylase inhibitor htpb in antitumor and antimetastatic mouse models |
| url | http://europepmc.org/articles/PMC3261198?pdf=render |
| work_keys_str_mv | AT jiunnminshieh mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT tzutangwei mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT yenantang mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT sinminghuang mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT weilingwen mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT meiyuchen mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT hungchicheng mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT santoshbsalunke mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT chingshihchen mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT pinpinlin mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT chientienchen mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels AT yichingwang mitochondrialapoptosisandfaksignalingdisruptionbyanovelhistonedeacetylaseinhibitorhtpbinantitumorandantimetastaticmousemodels |